Jens T Van Praet, Sophie Henrard, Chris Kenyon, Agnès Libois, Annelies Meuwissen, Anne-Sophie Sauvage, Anne Vincent, Jef Vanhamel, Gert Scheerder
{"title":"比利时 2024 年接触前预防使用指南。","authors":"Jens T Van Praet, Sophie Henrard, Chris Kenyon, Agnès Libois, Annelies Meuwissen, Anne-Sophie Sauvage, Anne Vincent, Jef Vanhamel, Gert Scheerder","doi":"10.1080/17843286.2024.2356337","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to develop a guidance on the use of pre-exposure prophylaxis (PrEP) for HIV tailored to the Belgian context.</p><p><strong>Methods: </strong>Different aspects of PrEP care were judged by an expert group of nine Belgian clinicians, seeking consensus for areas of controversies.</p><p><strong>Results: </strong>PrEP should be considered in HIV negative patients at high risk of acquiring HIV. Currently, only oral tenofovir/emtricitabine is available in Belgium for PrEP, which can be used daily, or also event-driven in cisgender men and trans women who are not taking exogenous estradiol-based hormones. Personal counselling directed at medication adherence and sexual health should have a central role in PrEP care. At the initial assessment clinicians should give attention to symptoms of an acute HIV infection, the patients' immunization status and renal function. A regular follow-up must be set up to diagnose HIV seroconversion, treat sexually transmitted infections, and manage side effects of PrEP.</p><p><strong>Conclusion: </strong>The Belgian guidance on the use of PrEP provides a point of reference for standard PrEP care in Belgium and will be periodically updated.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Belgian 2024 guidance on the use of pre-exposure prophylaxis.\",\"authors\":\"Jens T Van Praet, Sophie Henrard, Chris Kenyon, Agnès Libois, Annelies Meuwissen, Anne-Sophie Sauvage, Anne Vincent, Jef Vanhamel, Gert Scheerder\",\"doi\":\"10.1080/17843286.2024.2356337\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>We aimed to develop a guidance on the use of pre-exposure prophylaxis (PrEP) for HIV tailored to the Belgian context.</p><p><strong>Methods: </strong>Different aspects of PrEP care were judged by an expert group of nine Belgian clinicians, seeking consensus for areas of controversies.</p><p><strong>Results: </strong>PrEP should be considered in HIV negative patients at high risk of acquiring HIV. Currently, only oral tenofovir/emtricitabine is available in Belgium for PrEP, which can be used daily, or also event-driven in cisgender men and trans women who are not taking exogenous estradiol-based hormones. Personal counselling directed at medication adherence and sexual health should have a central role in PrEP care. At the initial assessment clinicians should give attention to symptoms of an acute HIV infection, the patients' immunization status and renal function. A regular follow-up must be set up to diagnose HIV seroconversion, treat sexually transmitted infections, and manage side effects of PrEP.</p><p><strong>Conclusion: </strong>The Belgian guidance on the use of PrEP provides a point of reference for standard PrEP care in Belgium and will be periodically updated.</p>\",\"PeriodicalId\":7086,\"journal\":{\"name\":\"Acta Clinica Belgica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Clinica Belgica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17843286.2024.2356337\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Clinica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17843286.2024.2356337","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
目的我们的目的是根据比利时的国情，制定一份艾滋病暴露前预防（PrEP）指南：由九名比利时临床医生组成的专家组对 PrEP 治疗的不同方面进行了判断，并就存在争议的领域寻求共识：结果：HIV 阴性患者感染 HIV 的风险较高，应考虑 PrEP。目前，比利时只有口服替诺福韦/恩曲他滨可用于 PrEP，该药物可每天使用，也可在不服用外源性雌二醇激素的顺性男性和变性女性中按事件驱动使用。针对服药依从性和性健康的个人咨询应在 PrEP 治疗中发挥核心作用。在初步评估时，临床医生应关注急性 HIV 感染的症状、患者的免疫状况和肾功能。必须进行定期随访，以诊断艾滋病病毒血清转换、治疗性传播感染并控制 PrEP 的副作用：比利时 PrEP 使用指南为比利时的标准 PrEP 护理提供了一个参考点，并将定期更新。
Belgian 2024 guidance on the use of pre-exposure prophylaxis.
Objectives: We aimed to develop a guidance on the use of pre-exposure prophylaxis (PrEP) for HIV tailored to the Belgian context.
Methods: Different aspects of PrEP care were judged by an expert group of nine Belgian clinicians, seeking consensus for areas of controversies.
Results: PrEP should be considered in HIV negative patients at high risk of acquiring HIV. Currently, only oral tenofovir/emtricitabine is available in Belgium for PrEP, which can be used daily, or also event-driven in cisgender men and trans women who are not taking exogenous estradiol-based hormones. Personal counselling directed at medication adherence and sexual health should have a central role in PrEP care. At the initial assessment clinicians should give attention to symptoms of an acute HIV infection, the patients' immunization status and renal function. A regular follow-up must be set up to diagnose HIV seroconversion, treat sexually transmitted infections, and manage side effects of PrEP.
Conclusion: The Belgian guidance on the use of PrEP provides a point of reference for standard PrEP care in Belgium and will be periodically updated.
期刊介绍：
Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine primarily publishes papers on clinical medicine, clinical chemistry, pathology and molecular biology, provided they describe results which contribute to our understanding of clinical problems or describe new methods applicable to clinical investigation. Readership includes physicians, pathologists, pharmacists and physicians working in non-academic and academic hospitals, practicing internal medicine and its subspecialties.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
